Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

AstraZeneca TLR7 agonist assessed in four clinical trials

June 8, 2012

Gene therapy for choroideremia enters clinic

June 8, 2012

First-in-patient trial evaluates GSK-2256098

June 7, 2012

First-in-human trial of LY-2228820 completed

June 7, 2012

Phase I trial assesses volasertib combination regimens for solid tumors

June 7, 2012

Phase II results reported on amatuximab

June 7, 2012

SDF-1 inhibition may limit transplant vasculopathy

June 6, 2012

Phase I study evaluates peptide vaccine including cancer/testis antigens

June 6, 2012

Clinical studies assess daily and twice-daily dosing of golvatinib

June 6, 2012

CalciMedica describes new class of immunomodulators

June 6, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...